Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

NCT06332274 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT06332274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06332274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 3
Overall status
Recruiting
Start date
April 16, 2025
Completion date
April 30, 2030
Enrollment
717 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, colo-rectal cancer, lung cancer, pancreas cancer, soft tissue sarcoma